Publication:
Phase 3 Randomized Study of Daratumumab (DARA) Plus Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned as Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Simple item page
dc.authorwosidMaiolino, Angelo/Aak-1471-2021
dc.authorwosidBraunstein, Marc/Jwp-8833-2024
dc.authorwosidLiu, Weiping/J-3954-2014
dc.authorwosidBeksac, Meral/D-6411-2013
dc.authorwosidUsmani, Saad/Hci-4676-2022
dc.authorwosidBahlis, Nizar Jacques/Jzc-9644-2024
dc.authorwosidGrosicki, Sebastian/Aag-2917-2019
dc.contributor.authorZweegman, Sonja
dc.contributor.authorFacon, Thierry
dc.contributor.authorHungria, Vania
dc.contributor.authorBahlis, Nizar J.
dc.contributor.authorVenner, Christopher P.
dc.contributor.authorBraunstein, Marc
dc.contributor.authorUsmani, Saad Z.
dc.date.accessioned2025-12-11T00:49:13Z
dc.date.issued2024
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Zweegman, Sonja] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlands; [Facon, Thierry] Univ Lille, Dept Hematol, CHU Lille, Lille, France; [Hungria, Vania] Clin Sao Germano, Sao Paulo, Brazil; [Bahlis, Nizar J.] Univ Calgary, Arnie Charbonneau Canc Res Inst, Calgary, AB, Canada; [Venner, Christopher P.] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada; [Venner, Christopher P.] BC Canc Vancouver Ctr, Vancouver, BC, Canada; [Braunstein, Marc] NYU Langone Hosp Long Isl, Perlmutter Canc Ctr, NYU Long Isl Sch Med, Dept Med,Div Oncol Hematol, Mineola, NY USA; [Pour, Ludek] Univ Hosp Brno, Brno, Czech Republic; [Tutusaus, Josep Marti] Hosp Mutua Terrassa, Barcelona, Spain; [Basu, Supratik] Staffordshire Univ, New Cross Hosp, Wolverhampton, England; [Basu, Supratik] Univ Wolverhampton, CRN West Midlands, NIHR, Wolverhampton, England; [Cohen, Yael C.] Tel Aviv Univ, Tel Aviv Sourasky Ichilov Med Ctr, Dept Hematol, Tel Aviv, Israel; [Cohen, Yael C.] Tel Aviv Univ, Fac Med, Tel Aviv, Israel; [Matsumoto, Morio] Natl Hosp Org, Shibukawa Med Ctr, Gunma, Japan; [Suzuki, Kenshi] Japanese Red Cross Cent Med Ctr, Shibuya, Tokyo, Japan; [Hulin, Cyrille] Univ Hosp, Hop Haut Leveque, Pessac, France; [Grosicki, Sebastian] Med Univ Silesia, Fac Hlth Sci Bytom, Dept Hematol & Canc Prevent Chorzow, Katowice, Poland; [Legiec, Wojciech Maciej] Med Univ Lublin, Bone Marrow Transplantat, Lublin, Poland; [Beksac, Meral] Istinye Univ, Ankara Liv Hosp, Ankara, Turkiye; [Maiolino, Angelo] Inst Amer Ensino Pesquisa & Inovacao, Rio De Janeiro, Brazil; [Takamatsu, Hiroyuki] Kanazawa Univ, Kanazawa Univ Hosp, Dept Hematol, Kanazawa, Japan; [Perrot, Aurore] Univ Toulouse, CHU Toulouse, IUCT O, IUCT O,UPS, Toulouse, France; [Turgut, Mehmet] Ondokuz Mayis Univ, Fac Med, Dept Internal Med, Div Hematol, Samsun, Turkiye; [Liu, Weiping] Janssen Res & Dev LLC, Shanghai, Peoples R China; [Wang, Jianping; Chastain, Katherine; Carson, Robin] Janssen Res & Dev LLC, Spring House, PA USA; [Vermeulen, Jessica] Janssen Res & Dev LLC, Leiden, Netherlands; [Lopez-Masi, Lorena] Janssen Res & Dev LLC, Raritan, NJ USA; [Rowe, Melissa] Janssen Res & Dev, High Wycombe, England; [Usmani, Saad Z.] Mem Sloan Kettering Canc Ctr, Div Hematol Oncol, Dept Med, Myeloma Serv, New York, NY USAen_US
dc.description.sponsorshipPfizer; Celgene; Amgen; AbbVie; Ono; BMS; Takeda; Bristol-Myers Squibb; Sanofi; GSK; Menarini Stemline; Janssen: Current Employment; Abbvie; Merck; Gilead; Array Biopharma; Pharmacyclicsen_US
dc.description.sponsorshipHonoraria; Janssen, BMS, GSK, Pfizer: Research Funding. Suzuki: Celgene: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Takeda: Honoraria; SRL: Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria; BMS: Honoraria, Research Funding; AbbVie: Honoraria; Janssen: Honoraria; Novartis: Honoraria; Ono: Honoraria. Beksac: BMS, Takeda, Janssen, Menarini, Amgen, GSK: Consultancy, Membership on an entity's Board of Directors or advi-sory committees; BMS, Janssen, Takeda, Sanofi: Speakers Bureau. Maiolino: Bristol Myers Squibb: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Janssen: Consultancy, Hon-oraria; Pfizer: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria. Takamatsu: Bristol-Myers Squibb: Honoraria, Research Funding; Sanofi: Honoraria; Ono: Honoraria; Janssen: Honoraria; SRL: Consultancy; Adaptive Biotechnologies: Consultancy. Perrot: BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Hon-oraria; Amgen: Honoraria; Abbvie: Honoraria; Menarini Stemline: Honoraria; Sanofi: Honoraria, Research Funding; Pfizer: Hon-oraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Liu: Janssen: Current Employment, Current holder of stock options in a privately-held company. Wang: Janssen: Current Employment, Current holder of stock options in a privately-held company. Chastain: Janssen: Current Employment, Current holder of stock options in a privately-held company. Vermeulen: Janssen: Current Employment, Current holder of stock options in a privately-held company. Krevvata: Janssen: Current Employment, Current holder of stock options in a privately-held company. Lopez-Masi: Janssen: Current Employment, Current holder of stock options in a privately-held company. Carey: Janssen: Current Employment, Current holder of stock options in a privately-held company. Rowe: Janssen: Current Employment, Current holder of stock options in a privately-held company. Carson: Janssen: Current Employment, Current holder of stock options in a privately-held company. Usmani:Abbvie: Consultancy, Research Funding; Gracell: Consultancy; Merck: Research Funding; GSK: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Gilead: Research Funding; Genentech: Consultancy; Sanofi: Consultancy, Research Funding; TeneoBio: Consultancy; Amgen: Consultancy, Research Funding; SeaGen: Consultancy, Re-search Funding; Array Biopharma: Research Funding; SkylineDX: Consultancy, Research Funding; Pfizer: Consultancy; Sanofi: Consultancy, Research Funding; SecuraBio: Consultancy; Bristol-Myers Squibb-Celgeneen_US
dc.description.woscitationindexScience Citation Index Expanded - Conference Proceedings Citation Index - Science
dc.identifier.doi10.1182/blood-2024-200871
dc.identifier.endpage364en_US
dc.identifier.issn0006-4971
dc.identifier.issn1528-0020
dc.identifier.scopusqualityQ1
dc.identifier.startpage362en_US
dc.identifier.urihttps://doi.org/10.1182/blood-2024-200871
dc.identifier.urihttps://hdl.handle.net/20.500.12712/39573
dc.identifier.volume144en_US
dc.identifier.wosWOS:001412359600012
dc.identifier.wosqualityQ1
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofBlooden_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titlePhase 3 Randomized Study of Daratumumab (DARA) Plus Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned as Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trialen_US
dc.typeConference Objecten_US
dspace.entity.typePublication

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu